Differences between TNM classification and 2-[18F]FDG PET parameters of primary tumor in NSCLC patients by Cegla, Paulina et al.
445https://journals.viamedica.pl/rpor
research paper
reports of practical Oncology and radiotherapy 




Address for correspondence: Paulina Cegla PhD, Nuclear Medicine Department, Greater Poland Cancer Centre, 61–866 Poznan, Poland, 
fax: +48 61 8850 785; email: paulina.cegla@gmail.com
Differences between TNM classification and 2-[18F]FDG PET 
parameters of primary tumor in NSCLC patients
Paulina Cegla 1, Maciej Bryl2, Kamila Witkowska3, Agnieszka Bos-Liedke4, Katarzyna Pietrasz1, 
Witold Kycler5, 6, Julian Malicki7, 8, Tomasz Piotrowski7, 8, Rafał Czepczyński3, 9
1Department of Nuclear Medicine, Greater Poland Cancer Centre, Poznan, Poland
2Oncology Department at Regional Centre of Lung Diseases in Poznan and Department of Thoracic Surgery, 
Poznan University of Medical Sciences, Poznań, Poland 
3Department of Nuclear Medicine, Affidea Poznań, Poland
4Department of Macromolecular Physics, Adam Mickiewicz University, Poznan, Poland
5Gastrointestinal Surgical Oncology Department, Greater Poland Cancer Centre, Poznan, Poland
6Department of Head and Neck Surgery, Poznan University of Medical Science, Poznan, Poland
7Chair and Department of Electroradiology, Poznan University of Medical Science, Poland
8Medical Physics Department, Greater Poland Cancer Centre, Poznan, Poland
9Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Science, Poland
This article is available in open access under creative common attribution-Non-commercial-No Derivatives 4.0 International (cc BY-Nc-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially
© 2021 Greater poland cancer centre.  









Lung cancer is the leading cause of death world-
wide in both sexes combined [1] and smoking is 
the main factor for developing lung cancer — it is 
responsible for 80% of cases in men and 50% in 
women [2]. There is a 16% 5-year survival rate in 
the United States, and 10% in Europe [3], thus it 
AbstrAct
background: The aim of the study was to compare the TNM classification with 2-[18F]FDG peT biological parameters of primary 
tumor in patients with NscLc. 
Materials and methods: retrospective analysis was performed on a group of 79 newly diagnosed NscLc patients. peT scans 
were acquired on Gemini TF peT/cT scanner 60–70 min after injection of 2-[18F]FDG with the mean activity of 364 ± 75 MBq, 
with the area being examined from the vertex to mid-thigh. The reconstructed peT images were evaluated using MIM 7.0 
software for sUVmax, MTV and TLG values. 
results: The analysis of the cancer stage according to TNM 8th edition showed stage Ia2 in 8 patients, stage Ia3 — 6 patients, 
stage IB — 4 patients, IIa — 3 patients, 15 patients with stage IIB, stage IIIa — 17 patients, IIIB — 5, IIIc — 5, IVa in 7 patients 
and stage IVB in 9 patients. The lowest TLG values of primary tumor were observed in stage Ia2 (11.31 ± 15.27) and the highest 
in stage IIIc (1003.20 ± 953.59). The lowest value of primary tumor in sUVmax and MTV were found in stage Ia2 (6.8 ± 3.8 and 
1.37 ± 0.42, respectively), while the highest sUVmax of primary tumor was found in stage IIa (13.4 ± 11.4) and MTV in stage IIIc 
(108.15 ± 127.24). 
conclusion: TNM stages are characterized by different primary tumor 2-[18F]FDG peT parameters, which might complement 
patient outcome.
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is important to develop more precise diagnostic 
tools allowing a reliable evaluation of the severity 
of the disease, which will lead to a personalized 
therapy.
Lung tumors are formed histologically from the 
respiratory epithelium and can be divided into two 
main groups: small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC). SCLC is more 
aggressive, grows faster and accounts for about 15% 
of cases. NSCLC (85% of cases) can be divided 
into four pathological subgroups: adenocarcinoma 
(AC), squamous cell carcinoma (SCC), large cell 
carcinoma (LCC) and NSCLC not otherwise speci-
fied (NOS) [4, 5].
Positron emission tomography with computed 
tomography (PET/CT) is a useful tool in assess-
ing various cancer types, because it allows the 
visualization of morphological changes which 
occur before anatomical changes. The most 
common radiopharmaceutical used for PET/CT 
studies is the glucose analogue labeled with 
Fluorine 18 (2-deoxy-2-[18F]fluoro-D-glucose, 
2-[18F]FDG) [6]. Many studies showed that meta-
bolic tumor volume (MTV) and total lesion gly-
colysis (TLG) are important prognostic factors 
in lung cancer patients [7] and provide better 
diagnostic information than maximum standard-
ized uptake value (SUVmax), because of better de-
termination of heterogeneity in the entire tumor 
volume [8].
The TNM (tumor, nodes, metastasis) classifica-
tion allows stage of disease to be assessed and the 
first version of the TNM system was published in 
1968. It was defined by the American Joint Com-
mittee on Cancer (AJCC) and the UICC. This 
system is based on the assessment of tumor size 
(T feature), lymph nodes involvement (N feature) 
and presence of distant metastases (M feature) 
[9]. The currently used 8th edition provides some 
changes as compared to the 7th edition,: the most 
important one is shown in stage I where T1a (mi) 
was added for minimally invasive adenocarcino-
ma, T feature has a new cut off point at 1 and 4 
cm [10]. Accurate diagnostic imaging, according 
to the criteria of this classification, is the basis for 
standard treatment [3]. 
The aim of the study was to compare the TNM 
classification with 2-[18F]FDG PET biological pa-
rameters (as SUVmax, MTV and TLG) of the primary 
tumor in patients with NSCLC.
Materials and methods
Retrospective analysis was performed on 79 
previously untreated patients (48M, 31F) with his-
tologically confirmed NSCLC examined between 
May 2009 and December 2014. The acquisition was 
performed 60–70 min after intravenous injection of 
2-[18F]FDG (FCON, Germany) with mean activity 
of 374 ± 75 MBq on Gemini TF 16  PET/CT scan-
ner (Philips). Patients after the administration of the 
isotope stayed in a darkened room with room tem-
perature to rest. 2-[18F]FDG PET/CT imaging was 
performed after fasting for at least 5 hours before the 
examination (mean glucose level 95 ± 18 mg/dL). 
The study protocol of the areas under examina-
tion extended from the vertex to mid-thigh, with 
1.30 min per one table, with 5-mm-thick slices. The 
study began with low-dose computed tomography 
(CT), afterwards PET acquisition was performed 
without changing the patient’s position. The recon-
structed PET images were evaluated using MIM 7.0 
Software (Cleveland, OH, USA).
Based on PET images several biological parameters: 
SUVmax, MTV and TLG were extracted for primary 
tumor. SUVmax was assessed as a maximum concen-
tration of radiotracer in the region of interest (ROI) 
taking into account patients’ weight and injected dose. 
MTV is one of the most important parameters 
assessed in PET images. There are several methods 
like the manual method or the gradient threshold 
method for defining tumor borders. In this study 
an appropriate method defining the volume of the 
primary tumor was selected based on our previous 
research [11].
TLG is a product of a SUVmean and MTV thus 
provides not only volumetric but also metabolic in-
formation of the tumor and it was first introduced 
by Larson et al. [12]. 
Normality of data distribution was assessed using 
the Kolmogorov-Smirnov or W Shapiro-Wilk tests. 
For statistical analysis, the Wilcoxon-Mann-Whit-
ney Test and T-Test were used. Pearson coefficients 
were used to estimate the correlation between pa-
rameters and statistical significance was defined as 
a p value less than 0.05. 
results
In the analyzed group, 31 patients were women, 
while 48 patients were men. In 38 patients NSCLC 
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was diagnosed in the left lung, while in 41 patients 
in right lung. The analysis of the TNM classifica-
tion showed stage IA2 in 8 patients, stage IA3 — 6 
patients, stage IB — 4 patients, IIA — 3 patients, 
IIB — 15, stage IIIA — 17 patients, in stage IIIB and 
IIIC — 5 patients each, IVA in 7 patients and stage 
IVB in 9 patients (Fig. 1).  
Differences of primary tumor biological param-
eters by stage are shown in Table 1. The highest SU-
Vmax values were found in stage IIA (13.4 ± 11.3) and 
the lowest in stage IA2 (6.8 ± 3.3). Statistically sig-
nificant differences were found between stage IA2 
and IA3 (p = 0.04), IA2 and IIIA and IIIB (p = 0.001 
and p = 0.02, respectively). Also statistically sig-
nificant differences in SUVmax values were shown 
between stage IB and IIIA (p = 0.03), stage IIB and 
IIIA (p = 0.008), stage IIB and IIIB (p = 0.02), IIB 
and IIIC (p = 0.03), IIIA and IVA (p = 0.02) and 
between stage IIIC and IVA (p = 0.0007). 
Comparison between TLG and TNM classifica-
tion showed that in stage IIIC TLG was significantly 
higher (p = 0.006) than in other stages (Fig.  2). 
The highest TLG values were found in stage IIIC 
(1003.20 ± 953.59) and the lowest in stage IA2 
(11.31 ± 15.27). Statistically significant differences 
were found between stage IA2 and IA3 (p = 0.01), 
IB (p = 0.022), IIA (p = 0.016), IIB (p = 0.014), IIIA 
(p < 0.001), IIIB (p = 0.008) and IIIC (p = 0.009). 
Stage IA3 showed significant differences between 
stage IIIIA, IIIB and IIIC (p = 0.007, p = 0.028 
and p = 0.0248, respectively). Stage IB showed sig-
nificant differences compared only to stage IIIA 
(p = 0.028). Stage IIB had statistically signifi-
cant different TLG values compared to stage IIIA 
(p = 0.002), IIIB (p = 0.010) and IIIC (p = 0.001). 
Stage IIIA showed significant differences between 
stage IIIC (p = 0.025) while stage IIIC with stage 
IVA (p = 0.034). 
The same observation was made when compar-
ing MTV and TNM classification (Fig. 3). Higher 
volumes of primary tumor were observed in pa-
tients with more advanced disease. However stage 
IVA showed lower MTV values than other stag-
es. The highest MTV values were found in stage 
IIIC (108.15 ± 127.24 cm3) and the lowest in stage 
table 1. Mean values for assessed primary tumor parameters
Stage SUVmax MTV [cm
3] TLG
Ia2 6.8 ± 3.3 1.37 ± 0.42 11.31 ± 15.27
Ia3 11.1 ± 5.9 6.27 ± 5.14 35.01 ± 22.17
IB 8.1 ± 2.8 11.14 ± 8.72 60.11 ± 58.77
IIa 13.4 ± 11.3 16.58 ± 13.77 170.41 ± 196.99
IIB 7.4 ± 4.0 19.49 ± 19.25 85.73 ± 87.06
IIIa 12.3 ± 4.1 68.10 ± 77.48 390.37 ± 316.48
IIIB 12.1 ± 5.2 49.44 ± 55.19 291.36 ± 287.38
IIIc 8.2 ± 12.4 108.15 ± 127.24 1003.20 ± 953.59
IVa 8.7 ± 3.9 31.05 ± 33.93 156.40 ± 247.26
IVB 9.4 ± 7.0 60.02 ± 131.15 345.79 ± 655.78
sUVmax — maximum the standarized uptake volume; MTV — metabolic tumor volume; TLG — total lesion glycolysis
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IA2 (1.37 ± 0.42 cm3). Statistically significant dif-
ferences were found between stage IA2 and IA3 
(p = 0.009), IB (p = 0.003), IIA (p = 0.004), IIB 
(p = 0.008), IIIA (p = 0.001), IIIB (p = 0.013), IIIC 
(p = 0.003) and IVA (p = 0.014). Stage IA3 showed 
statistically significant differences between stage IB 
(p = 0.017), IIIA (p = 0.026), IIIB (p = 0.043) and 
IIIC (p = 0.011). Stage IB showed significant differ-
ences in MTV only between stage IIIC (p = 0.036), 
while stage IIB between stage IIIA (p = 0.009), IIIB 
(p = 0.039) and IIIC (p = 0.001). Significant differ-
ences in MTV values were also found between stage 
IIIC and IVA (p = 0.024).
Figure 4 shows an example of discrepancy be-
tween the TNM classification and metabolic pa-
rameters. Patient A with very high activity within 
tumor mass in the left lung without any nodal and 
metastatic disease — so the TNM stage is IB and 
patient B with a small primary tumor (supposed to 
be classified as IA stage), however with brain metas-
tasis grouping patient as stage IVB. 
Discussion
NSCLC is the most common histopathological 
type of lung cancer with a poor prognosis [4]. Cur-
rently the TNM classification is the prognostic fac-
tor for patients with NSCLC. Based on this system, 
patients are classified into 4 stages according to the 
extent of the disease and each stage represent a het-
erogeneous group of patients. However, despite the 
proven benefits, the TNM classification has the limi-
tations of a pure morphological assessment [13]. 
PET/CT with commonly used 2-[18F]FDG is used 
in patients with various cancer disease (including 
NCSLC) for staging, radiotherapy planning and as-
sessing response to therapy [14, 15]. It provides in-
formation not only about anatomical changes in pa-
tients’ body, but what is more important, provides 
metabolic information [16]. Commonly 2-[18F]
FDG images are assessed using SUVmax which, ac-
cording to some authors, is a prognostic factor for 
several cancers [17], thus SUVmax should represent 
higher values in patients with more advanced stag-
es. In our study the highest values were shown in 
less advanced stages which is not in concordance 
with the above statement. Some patients in less 
advanced stages showed higher SUVmax values than 
patients in advanced stages and the explanation of 
this finding might be found in Figure 4. Also, the 
biggest limitation of using the SUVmax value is that 
it represents a single maximum pixel within the tu-
mor without the possibility of reflecting metabolic 
activity within the entire tumor. Beside that, some 
other factors may indicate the SUVmax like: blood 
glucose level, ROI definition, image reconstruction 
method, body composition etc. [18]. 
Other parameters that can be obtained from 
2-[18F]FDG PET/CT study are of increasing inter-
est. One of such parameters is MTV which reflects 
the volume of metabolically active tumor. In some 
studies, it has been shown that MTV is an inde-
pendent prognostic factor for lung cancer patients 
[19]. There are also several studies where authors 
concluded that tumor volumes assessed in 2-[18F]
FGD PET/CT images are more accurate than those 
determined by computed tomography (CT) or 
magnetic resonance imaging (MRI) alone [20]. In 
our study higher MTV values were observed in 
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Figure 4. Discrepancy between TNM classification 
and metabolic parameters assessed in 2-[18F]FDG peT/cT
a B
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patients with more advanced stages; however, the 
highest value was found in stage IIIC and it cannot 
be explained by the T feature because T3 is also 
a part of stages IIB, IIIA and IIIB where MTV rep-
resents lower values. 
Another interesting metabolic parameter is TLG 
which was also concluded as a better prognostic 
factor for NSCLC than SUVmax [21–23]. TLG in-
cludes metabolic and volumetric information thus 
reflects changes in the whole tumor and is more 
accurate than a single pixel measured in SUVmax 
and can give a more accurate prognostic measure 
to the TNM classification. We also showed that 
TLG varies with TNM stage. Statistically significant 
higher values were shown in stage IIIC which might 
be partially explained by the fact that this stage 
includes patients with big tumors (T3) (MTV also 
showed the highest values in this stage); however, 
cannot be explained by nodal involvement because 
in this study we assessed only primary tumor pa-
rameters. 
One of the major limitations of this study is 
a small group of patients; however, based on this 
small group we confirmed that metabolic param-
eters expressed in 2-[18F]FGD PET/CT study differ 
from the TNM classification. While in the lowest 
stages these parameters are lower; there are sig-
nificant differences in more advanced stages which 
might have an influence on the management of 
patients with NSCLC. Moreover, this might also 
suggest two different cancer behaviors: in stage III 
cancer tends to grow locally, while in stage IV has 
a tendency to metastasize, which not always cor-
responds to tumor size. However, further studies 
on a bigger group of patients are needed to confirm 
this statement.
conclusion
Metabolic parameters of the tumor expressed 
with MTV and TLG vary with TNM stage and can 
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